Biote cuts FY25 revenue view to over $190M from $202M-$208M
Revised Financial Guidance: Biote has adjusted its fiscal 2025 revenue guidance to over $190 million and its Adjusted EBITDA guidance to over $50 million due to ongoing restructuring efforts.
Commitment to Strategic Goals: The company emphasizes its strong liquidity and commitment to advancing patient health while focusing on long-term value creation for stakeholders amidst organizational changes.
Trade with 70% Backtested Accuracy
Analyst Views on BTMD
About BTMD
About the author
Biote Corp Reports Decrease in Q3 Earnings
- Earnings Decline: biote Corp reported a third-quarter profit of $8.19 million, down from $10.70 million in the same period last year.
- Earnings Per Share: The earnings per share (EPS) decreased to $0.22 from $0.33 year-over-year.
- Revenue Drop: The company's revenue fell by 6.7% to $47.96 million, compared to $51.38 million in the previous year.
- Financial Overview: Key financial metrics indicate a decline in both earnings and revenue for biote Corp compared to the prior year.
Capricor (CAPR) Rises 5.3%: Could This Signal More Upside Ahead?
Capricor Therapeutics Stock Performance: Capricor Therapeutics (CAPR) shares rose 5.3% to $6.52, driven by a positive regulatory update on its Deramiocel program for Duchenne muscular dystrophy, which may expedite the drug's market entry.
Earnings Expectations and Market Position: The company is projected to report a quarterly loss of $0.54 per share, with revenues expected to increase by 6.2% year-over-year. The consensus EPS estimate has remained stable, indicating potential stock price movements may depend on future earnings revisions.
